



SASKATCHEWAN FORMULARY BULLETIN

Update to the 62nd Edition of the Saskatchewan Formulary

<u>Product</u>	<u>DIN</u>	<u>Pre-Markup (\$)</u>	<u>Unit Price (\$)</u>
----------------	------------	------------------------	------------------------

New Non-Interchangeable Full Formulary Listings Effective July 1, 2012:

Contour NEXT (BAY)

Blood Glucose Test Strip	97799459	0.6989	0.7583
--------------------------	----------	--------	--------

Rapid Response (BTN)

Blood Glucose Test Strip	97799451	0.7100	0.7704
--------------------------	----------	--------	--------

Euro K600 (Potassium Chloride) (EUR)

600mg long acting tablet	02246734	0.0450	0.0477
--------------------------	----------	--------	--------

Euro K20 (Potassium Chloride) (EUR)

1500mg long acting tablet	02242261	0.1995	0.2115
---------------------------	----------	--------	--------

New Exception Drug Status (EDS) Listings Effective July 1, 2012:

Trajenta tablet (linagliptin) (BOE)

5mg tablet	02370921	2.5500	2.7668
------------	----------	--------	--------

For treatment of patients with Type 2 diabetes who have had previous prescriptions for metformin and a sulfonylurea.

Please Note: *These products should be used in patients with diabetes who are not adequately controlled on or are intolerant to metformin and a sulfonylurea, and for whom insulin is not an option.*

- *Due to greater evidence of long-term benefit and enhanced cost-effectiveness, patients should be tried on metformin, sulfonylureas, and insulin NPH before considering other agents.*
- *Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available as a full formulary benefit).*
- *Drug Plan coverage is intended for linagliptin as part of combination diabetes treatment (e.g., not as monotherapy).*

Product	DIN	Pre-Markup (\$)	Unit Price (\$)
Edurant tablet (rilpivirine) (JAN) 25mg tablet	02370603	13.7970	14.9698

For management of HIV disease.

This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Banzel tablet (rufinamide) (EIS) 100mg tablet	02369613	0.8423	0.9139
200mg tablet	02369621	1.5810	1.7154
400mg tablet	02369648	3.1298	3.3959

For the adjunctive treatment of patients with Lennox-Gastaut Syndrome who are under the care of a physician experienced in treating Lennox-Gastaut Syndrome associated seizures, and are currently receiving two or more antiepileptic drugs (one of which should be lamotrigine or topiramate).

Complera tablet, (emtricitabine/rilpivirine/tenofovir DF) (GSI) 200mg/25mg/300mg	02374129	39.6040	41.2707
--	----------	---------	---------

For the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naïve patients, or to replace the three components given as dual or triple therapy.

This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Additional Formulation of a Current Exception Drug Status (EDS) Listing Effective July 1, 2012:

Actonel DR tablet (risedronate sodium) (WCI) 35mg delayed release tablet	02370417	12.3375	13.3862
--	----------	---------	---------

For treatment of:

- (a) Osteoporosis in patients unresponsive to etidronate disodium/calcium (Didrocal) after receiving it for one year.
- (b) Osteoporosis in patients intolerant to etidronate disodium/calcium (Didrocal).
- (c) Osteoporosis in patients who have pre-existing and/or recent fractures.
- (d) Glucocorticoid-induced osteoporosis in patients who have received systemic glucocorticoid treatment for at least 3 months.

Eprex pre-filled syringe (epoetin alfa) (JAN) 30,000IU/0.75ml	02288680	428.32	464.73
40,000IU/ml	02240722	428.32	464.73

For treatment of:

- (a) Anemia in chronic renal disease patients prior to initiation of dialysis.

Note: Coverage for dialysis patients is provided under the Saskatchewan Aids to Independent Living (S.A.I.L.) Program. Exception Drug Status coverage is not required for S.A.I.L. patients.

- (b) Anemia in AIDS patients.
- (c) Anemia in transplant patients.

Product	DIN	Pre-Markup (\$)	Unit Price (\$)
Onglyza tablet (saxagliptin) (BMY) 2.5mg tablet	02375842	2.3000	2.4955

For the treatment of patients with type 2 diabetes who have had previous prescriptions for metformin and a sulfonylurea.

Please Note: *These products should be used in patients with diabetes who are not adequately controlled on or are intolerant to metformin and a sulfonylurea, and for whom insulin is not an option.*

- *Due to greater evidence of long-term benefit and enhanced cost-effectiveness, patients should be tried on metformin, sulfonylureas, and insulin NPH before considering other agents.*
- *Patients intolerant to glyburide may try another sulfonylurea (e.g., gliclazide, which is available as a full formulary benefit).*
- *Drug Plan coverage is intended for saxagliptin as part of combination diabetes treatment (e.g., not as monotherapy).*

Revised Exception Drug Status Criteria (see italicized portion) Effective July 1, 2012:

- **Aclasta** solution for injection 5mg/100ml (zoledronic acid) (NVR)
 - (a) For symptomatic treatment of Paget’s disease of the bone.
 - (b) *For the treatment of postmenopausal osteoporosis in women who would otherwise meet the current EDS criteria for oral bisphosphonates, but for whom oral bisphosphonates are contraindicated due to hypersensitivity (i.e. an allergic reaction) or abnormalities of the esophagus (e.g. esophageal stricture or achalasia) and have at least two of the following:*
 - i) *age > 75 years*
 - ii) *a prior fragility fracture*
 - iii) *a bone mineral density (BMD) T-score ≤ -2.5*

Note: Only one treatment per year is required.

Drugs Reviewed and Not Approved for Listing in the Saskatchewan Formulary:

- **Targin**, controlled release tablet, 10mg/5mg, 20mg/10mg, 40mg/20mg (oxycodone HCl/naloxone HCl) (PFR)
- **Onsolis**, buccal soluble film, 200mcg, 400mcg, 600mcg, 800mcg, 1200mcg (fentanyl citrate) (MVC)
- **Ozurdex**, intravitreal implant, 0.7mg (dexamethasone) (ALL)
- **Rapaflo**, capsule, 4mg, 8mg (silodosin) (WAT)

**Saskatchewan Ministry of Health
Drug Plan and Extended Benefits Branch
2nd Floor, 3475 Albert Street
Regina, Saskatchewan S4S 6X6
(306) 787-3317
1-800-667-7581**

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Ministry of Health. Inquiries should be directed to the address or telephone numbers shown at left.